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Dysfunction of the respiratory muscles (particularly the diaphragm) can compromise 37 
ventilation, pulmonary gas exchange, and oxygen delivery to the tissues. This is especially 38 
true for patients with heart failure (HF), where a loss in respiratory muscle strength and 39 
endurance capacity is common [1-4]. Inspiratory muscle weakness in HF causes heightened 40 
breathlessness, exertional intolerance, and reduces health-related quality-of-life [5-7]. The 41 
clinical importance of respiratory muscle weakness has also been clearly demonstrated. For 42 
example, Meyer et al. [5] reported that maximal inspiratory mouth pressure (MIP) is a strong 43 
predictor of survival in patients with HF, and in doing so were the first to highlight reduced 44 
inspiratory muscle strength as a novel, independent predictor of prognosis in these patients.  45 
 46 
In this issue of Journal of Cardiac Failure, Miyagi and colleagues [8] provide further evidence 47 
supporting the clinical significance of diaphragm dysfunction in patients with HF. In a detailed, 48 
retrospective study, the authors obtained ultrasonography derived measures of diaphragm 49 
muscle thickness in 77 patients (final sample size) hospitalised with a primary diagnosis of 50 
HF. Proposing that diaphragm thickness at total lung capacity ³'7-LQVS´ reflects both muscle 51 
mass and contractility (i.e. a comprehensive indicator of diaphragm function), it was found that 52 
44% of patients presented with diaphragm dysfunction (DT-insp < 4.0 mm). Intriguingly, 53 
compared to µQRUPDO¶ patients (DT-LQVS   PP WKRVH classified as having diaphragm 54 
dysfunction were generally older with higher values of left ventricular ejection fraction (>55%). 55 
Indeed, over half of the patients defined as having impaired diaphragm function were HF 56 
patients with a preserved ejection fraction (HFpEF), which begs the question: is the 57 
pathophysiological development of respiratory muscle dysfunction/weakness particularly 58 
prevalent in this distinct clinical syndrome? [9]. Perhaps unsurprisingly, patients with impaired 59 
diaphragm function also had worse lung function (vital capacity ~0.4 L lower) and lower MIP 60 
(~48 vs. 62 cmH2O) compared to patients with preserved diaphragm function. Importantly, 61 
lower DT-insp was associated with a significant impairment in 6-minute walk distance 62 
independent of the presence of dynapenia (i.e. limb muscle weakness unrelated to neurologic 63 
or muscular disease) in the patient cohort. In combination, the aforementioned findings 64 
suggest that diaphragm thickness may represent a functional index of inspiratory muscle 65 
weakness and independently predict exertional limitation in HF. So, given its functional 66 
importance and prognostic significance, we ask two questions: 1) should inspiratory muscle 67 
dysfunction and/or weakness now be assessed as standard clinical routine; and 2) should 68 
future research target the identification of novel interventions to combat respiratory muscle 69 
dysfunction to improve short- and long-term outcomes in patients with HF?  70 
 71 
 72 
 73 
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To answer our first question; Miyagi et al. [8] evaluate inspiratory muscle function using  74 
spirometry and diaphragm muscle ultrasound routinely as part of the standard rehabilitation 75 
program for HF patients hospitalised at their facility. However, in our experience, the use of 76 
ultrasound to assess inspiratory muscle function is far from standard practice in the vast 77 
majority of clinics. In addition, the examination of diaphragm muscle thickness using 78 
ultrasound requires in-depth expert training, is time consuming, and relies upon highly 79 
specialised (and typically very expensive) equipment. Perhaps more importantly, the definition 80 
of impaired diaphragm function presented (i.e. DT-insp < 4.0 mm) seems somewhat arbitrary 81 
and potentially rather severe. Indeed, a recent report in healthy humans suggested a lower 82 
limit of normal for diaphragm thickness at functional residual capacity and at total lung capacity 83 
of 1.5 mm and 1.8 mm, respectively [10]. These considerations, combined with a relative lack 84 
of normal reference values for diaphragm thickness in the general population, likely limit the 85 
utility of ultrasonography to assess diaphragm dysfunction as standard in the clinical setting. 86 
By contrast, the measurement of MIP is non-invasive, straightforward, quick and cost-87 
effective. Despite its dependence upon patient voluntary effort, MIP can provide an accurate 88 
indication of the presence and severity of inspiratory muscle weakness when performed in line 89 
with current recommendations and expressed relative to normative values [11, 12]. As such, 90 
if inspiratory muscle dysfunction and/or weakness is to be assessed as standard clinical 91 
routine, we propose that the measurement of MIP represents the most feasible option.     92 
 93 
To answer our second question; the data presented by Miyagi et al. [8] provide robust support 94 
for implementing therapeutic interventions designed to abate the decline in inspiratory muscle 95 
strength in HF patients. Specific inspiratory muscle training has been shown to improve 96 
functional indices, reduce symptoms, and decrease hospital readmissions in HF patients [13]. 97 
As Miyagi et al. [8] astutely suggested, one mechanism of action for any improvement in 98 
H[HUFLVH FDSDFLW\ IROORZLQJ LQVSLUDWRU\ PXVFOH WUDLQLQJ PD\ EH WKURXJK D µEOXQWLQJ¶ RI WKH99 
respiratory muscle metaboreflex, such that the fraction of cardiac output required by the 100 
inspiratory muscles and the reflex vasoconstrictive effects on the limb muscles (secondary to 101 
the release of fatigue-induced metabolites from the inspiratory muscles) during exercise would 102 
be reduced [14]. While inspiratory muscle training has been recognized as a potential 103 
treatment strategy to improve exercise tolerance in HF, it does little to identify the underlying 104 
cause of inspiratory muscle dysfunction and/or weakness in these patients.  105 
 106 
At the cellular level, most evidence from experimental models has confirmed diaphragm 107 
dysfunction in HF is characterized by an increase in reactive oxygen species that act to impair 108 
excitation-contraction coupling, which is paralleled by an upregulation in signalling pathways 109 
related to atrophy (e.g., ubiquitin proteasome pathway). However, most of these conclusions 110 
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have been drawn from our classic HF phenotype. The recent study by Miyagi et al. [8] clearly 111 
highlights that more data are urgently needed in relation to HFpEF. We have confirmed that 112 
rats with HFpEF similarly demonstrate significant impairments to contractile function in 113 
isolated diaphragm fibers [15, 16], with impaired mitochondrial complex I function appearing 114 
as one key mechanism. Importantly, this was attenuated by endurance exercise training [16]. 115 
We have also revealed that diaphragm weakness in mice with cardiac failure was overcome 116 
in vivo following treatment with a small-molecule inhibitor targeting the E3 ligase MuRF1 (i.e. 117 
a key step in the atrophy pathway) [17]. Collectively, therefore, these recent data provide 118 
encouraging evidence that it is possible to prevent diaphragm dysfunction in HF by in vivo 119 
drug treatment in addition to exercise training. However, identifying further underlying cellular 120 
mechanisms should remain a key target for future research.  121 
 122 
 123 
 124 
 125 
 126 
 127 
 128 
 129 
 130 
 131 
 132 
 133 
 134 
 135 
 136 
 137 
 138 
 139 
 140 
 141 
 142 
 143 
 144 
 145 
 146 
5 
 
REFERENCES 147 
 148 
[1] Ambrosino N, Opasich C, Crotti P, Cobelli F, Tavazzi L, Rampulla C. Breathing pattern, 149 
ventilatory drive and respiratory muscle strength in patients with chronic heart failure. Eur 150 
Respir J. 1994;7:17-22. 151 
[2] Lindsay DC, Lovegrove CA, Dunn MJ, Bennett JG, Pepper JR, Yacoub MH, et al. 152 
Histological abnormalities of muscle from limb, thorax and diaphragm in chronic heart failure. 153 
Eur Heart J. 1996;17:1239-50. 154 
[3] Mancini DM, Henson D, LaManca J, Levine S. Respiratory muscle function and dyspnea 155 
in patients with chronic congestive heart failure. Circulation. 1992;86:909-18. 156 
[4] McParland C, Krishnan B, Wang Y, Gallagher CG. Inspiratory muscle weakness and 157 
dyspnea in chronic heart failure. Am Rev Respir Dis. 1992;146:467-72. 158 
[5] Meyer FJ, Borst MM, Zugck C, Kirschke A, Schellberg D, Kubler W, et al. Respiratory 159 
muscle dysfunction in congestive heart failure: clinical correlation and prognostic significance. 160 
Circulation. 2001;103:2153-8. 161 
[6] Ribeiro JP, Chiappa GR, Neder JA, Frankenstein L. Respiratory muscle function and 162 
exercise intolerance in heart failure. Curr Heart Fail Rep. 2009;6:95-101. 163 
[7] van der Palen J, Rea TD, Manolio TA, Lumley T, Newman AB, Tracy RP, et al. Respiratory 164 
muscle strength and the risk of incident cardiovascular events. Thorax. 2004;59:1063-7. 165 
[8] Miyagi M, Kinugasa Y, Sota T, Yamada K, Ishisugi T, Hirai M, et al. Diaphragm Muscle 166 
Dysfunction in Patients With Heart Failure. J Card Fail. 2017. 167 
[9] Yamada K, Kinugasa Y, Sota T, Miyagi M, Sugihara S, Kato M, et al. Inspiratory Muscle 168 
Weakness is Associated With Exercise Intolerance in Patients With Heart Failure With 169 
Preserved Ejection Fraction: A Preliminary Study. J Card Fail. 2016;22:38-47. 170 
[10] Boon AJ, Harper CJ, Ghahfarokhi LS, Strommen JA, Watson JC, Sorenson EJ. Two-171 
dimensional ultrasound imaging of the diaphragm: quantitative values in normal subjects. 172 
Muscle Nerve. 2013;47:884-9. 173 
[11] American Thoracic Society/European Respiratory S. ATS/ERS Statement on respiratory 174 
muscle testing. Am J Respir Crit Care Med. 2002;166:518-624. 175 
[12] Sclauser Pessoa IM, Franco Parreira V, Fregonezi GA, Sheel AW, Chung F, Reid WD. 176 
Reference values for maximal inspiratory pressure: a systematic review. Can Respir J. 177 
2014;21:43-50. 178 
[13] Cahalin LP, Arena RA. Breathing exercises and inspiratory muscle training in heart failure. 179 
Heart Fail Clin. 2015;11:149-72. 180 
[14] Chiappa GR, Roseguini BT, Vieira PJ, Alves CN, Tavares A, Winkelmann ER, et al. 181 
Inspiratory muscle training improves blood flow to resting and exercising limbs in patients with 182 
chronic heart failure. J Am Coll Cardiol. 2008;51:1663-71. 183 
6 
 
[15] Bowen TS, Brauer D, Rolim NPL, Baekkerud FH, Kricke A, Ormbostad Berre AM, et al. 184 
Exercise Training Reveals Inflexibility of the Diaphragm in an Animal Model of Patients With 185 
Obesity-Driven Heart Failure With a Preserved Ejection Fraction. J Am Heart Assoc. 2017;6. 186 
[16] Bowen TS, Rolim NP, Fischer T, Baekkerud FH, Medeiros A, Werner S, et al. Heart failure 187 
with preserved ejection fraction induces molecular, mitochondrial, histological, and functional 188 
alterations in rat respiratory and limb skeletal muscle. Eur J Heart Fail. 2015;17:263-72. 189 
[17] Bowen TS, Adams V, Werner S, Fischer T, Vinke P, Brogger MN, et al. Small-molecule 190 
inhibition of MuRF1 attenuates skeletal muscle atrophy and dysfunction in cardiac cachexia. 191 
J Cachexia Sarcopenia Muscle. 2017;8:939-53. 192 
 193 
